Why is Grail facing a securities class action lawsuit?

Investors allege Grail made misleading statements about the prospects and design of its NHS-Galleri cancer screening trial.

What is the NHS-Galleri study mentioned in the Grail lawsuit?

NHS-Galleri is a large cancer screening trial evaluating whether early detection can reduce the incidence of late-stage cancers.

What are investors alleging about the NHS-Galleri trial?

The complaint claims the trial was unlikely to demonstrate its primary endpoint within the planned timeframe.

Why is the trial timeline important in the Grail lawsuit?

Investors allege the three-year follow-up period may have been insufficient to demonstrate the desired outcome.

What are investors claiming Grail failed to disclose?

Plaintiffs claim the company did not fully reveal risks that the study might not achieve its primary endpoint as designed.

What are top-line results in a clinical trial?

Top-line results are preliminary findings released before full datasets and detailed analyses become available.

Why are detailed clinical trial results important to investors?

Detailed data helps investors assess whether positive summaries accurately reflect the study’s performance and risks.

What are investors alleging about Grail’s public statements?

The lawsuit claims the company overstated confidence in the trial’s success and future prospects.

How could trial setbacks affect Grail’s stock price?

Concerns about study outcomes and regulatory prospects may reduce investor confidence and company valuation.

Who may qualify to participate in the Grail class action?

Investors who purchased Grail securities between May 13, 2025 and February 19, 2026 may be eligible if they suffered losses.

What is the deadline to seek lead plaintiff status in the Grail lawsuit?

Investors seeking appointment as lead plaintiff must file a motion by August 4, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims against a company for misleading statements or omissions.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe during which alleged misleading statements occurred and investors may have purchased securities.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor selected by the court to represent the interests of all shareholders and help direct the litigation.

Grail, Inc. - Faruqi & Faruqi LLP

Q: What is the primary endpoint in the NHS-Galleri study?

The key objective was to show a statistically significant reduction in Stage III and Stage IV cancer diagnoses.

Grail, Inc.

Join Action

Case Details

Ticker GRAL

Class Period 05/13/2025 - 02/19/2026

Lead Plaintiff Deadline 08/04/2026

Days Left to Seek Plaintiff

If you are a Grail investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Grail To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Grail between May 13, 2025 and February 19, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Grail, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Defendants provided investors with material information concerning the likelihood of success of Grail’s NHS-Galleri trial achieving its primary endpoint of a statistically significant reduction in Stage III & IV cancers. Defendants’ statements included, among other things, confidence in the success of Galleri, consistently promoting its effectiveness “in the real world” and the positive predictive value (“PPV”) observed in the Pathfinder studies and in NHS-Galleri’s top-line results as sources of confidence for its potential. Defendants further routinely touted the design of the NHS-Galleri and how three years were necessary to demonstrate the achievability of the primary endpoint.

Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Grail’s NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as Defendants have since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; Defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint was achievable. Defendants further repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines which arguably suggested either a longer timeline would be necessary or otherwise that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial’s end had been reduced

Lead Plaintiff Deadline: August 4, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Grail, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify